Current status of gene expression profiling of pancreatic cancer.

Pancreatic cancer is an important cause of morbidity and mortality but there are presently few if any prognostic markers available beyond tumour stage and grade. As tumours are detected and treated at earlier stages these factors are less prognostically informative and there is a growing need for development of novel diagnostic markers to guide pre- and post-operative treatment. Additionally the outcome of surgery for pancreatic cancer remains poor, largely due to late clinical presentation of most cases, and early detection, particularly in high risk groups, such as those with chronic pancreatitis, Intraductal papillary mucinous cystadenoma (IPMN) would enable earlier surgical intervention and improved survival. Use of gene expression profiles represents an innovative approach to cancer classification and prognostication and has been applied to an increasingly wide range of cancers. Recent studies have identified prognostically informative gene signatures for pancreatic cancer, and there is now an urgent need to develop methods for their measurement in routine clinical samples.

[1]  J. Devière,et al.  Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. , 1991, Gastroenterology.

[2]  Hiroyuki Mano,et al.  Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells , 2005, Cancer science.

[3]  A. Biesbrock,et al.  Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). , 1993, The Journal of biological chemistry.

[4]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[5]  A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413) , 2000, Investigational New Drugs.

[6]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[7]  Rork Kuick,et al.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. , 2003, Cancer research.

[8]  B. Wiedenmann,et al.  Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis , 2001, Gut.

[9]  Haiyong Han,et al.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.

[10]  H. Sasano,et al.  An immunohistochemical study of the c‐erbB‐2 oncogene product in intraductal mucin‐hypersecreting neoplasms and in ductal cell carcinomas of the pancreas , 1993, Cancer.

[11]  T. Terada,et al.  EXPRESSION OF MUC APOMUCINS IN NORMAL PANCREAS AND PANCREATIC TUMOURS , 1996, The Journal of pathology.

[12]  W. Kuo,et al.  Human gastric mucin. Identification of a unique species by expression cloning. , 1993, The Journal of biological chemistry.

[13]  Eithne Costello,et al.  Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis , 2004, International journal of cancer.

[14]  K. Chayama,et al.  Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma , 2003, Cancer science.

[15]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[16]  R. Kuick,et al.  The Molecular Basis of Pancreatic Fibrosis: Common Stromal Gene Expression in Chronic Pancreatitis and Pancreatic Adenocarcinoma , 2004, Pancreas.

[17]  S. Goodman,et al.  Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.

[18]  Tatjana Crnogorac-Jurcevic,et al.  Expression profiling of microdissected pancreatic adenocarcinomas , 2002, Oncogene.

[19]  B Johansson,et al.  Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer , 1997, Genes, chromosomes & cancer.

[20]  L. Frati,et al.  Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. , 1998, American journal of clinical oncology.

[21]  Kimberly Walter,et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. , 2002, The American journal of pathology.

[22]  L. Chin,et al.  High-resolution characterization of the pancreatic adenocarcinoma genome , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Iovanna,et al.  Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Iovanna,et al.  Expression of p8 in human pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  M. Tatsuta,et al.  Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique , 1992, Cancer.

[26]  P. Lichter,et al.  Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. , 1996, Cancer research.